Stabilized antibody protein solutions

1. An aqueous solution comprising

(i) a monoclonal antibody; and

(ii) a stabilizing amount of arginine, methionine, and a C3 polyol;

wherein the concentration of methionine is 2-50 mM and the ratio of arginine to methionine (mM/mM) is 1:1-10:1.

2. The aqueous solution of claim 1 , wherein the C3 polyol is 1,2-propanediol, glycerol, or a mixture of 1,2-propanediol and glycerol.

3. The aqueous solution of claim 1 , wherein the C3 polyol is present at a concentration of about 100 mM to about 500 mM.

4. The aqueous solution of claim 1 , wherein the monoclonal antibody is a therapeutic antibody.

5. The aqueous solution of claim 1 , wherein the monoclonal antibody is trastuzumab.

6. The aqueous solution of claim 1 , wherein the monoclonal antibody is bevacizumab.

7. The aqueous solution of claim 1 , wherein the monoclonal antibody is selected from trastuzumab, rituximab, bevacizumab, cetuximab and ipilimumab.

8. The aqueous solution of claim 1 , wherein the monoclonal antibody is rituximab, bevacizumab, or adalimumab.

9. The aqueous solution of claim 1 , wherein the monoclonal antibody is rituximab.

10. The aqueous solution of claim 1 , wherein the monoclonal antibody is adalimumab.

11. The aqueous solution of claim 1 , wherein the monoclonal antibody is cetuximab.

12. The aqueous solution of claim 1 , wherein the monoclonal antibody is present at a concentration of about 1 mg/mL to about 300 mg/mL.

13. The aqueous solution of claim 1 , wherein the arginine is present at a concentration of about 5 mM to about 100 mM.

14. The aqueous solution of claim 1 , wherein the pH of the solution is between about pH 5.0 and about pH 7.0.

15. The aqueous solution of claim 1 , further comprising a buffer.

16. The aqueous solution of claim 1 , further comprising a non-ionic surfactant.

17. The aqueous solution of claim 1 , further comprising an uncharged tonicity modifier.

18. The aqueous solution of claim 1 , further comprising a charged tonicity modifier.

19. The aqueous solution of claim 1 , wherein the aqueous solution is isotonic.

20. The aqueous solution of claim 1 , further comprising a preservative.

21. The aqueous solution of claim 1 , which is formulated for administration by subcutaneous or intramuscular injection or by intravenous injection or infusion.

22. The aqueous solution of claim 1 , wherein the C3 polyol is present at a concentration of about 150 mM to about 400 mM.

23. The aqueous solution of claim 1 , wherein the C3 polyol is 1,2-propanediol.

24. The aqueous solution of claim 1 , wherein the C3 polyol is glycerol.

25. The aqueous solution of claim 1 , wherein the C3 polyol is a mixture of 1,2-propanediol and glycerol.

26. The aqueous solution of claim 1 , wherein the monoclonal antibody is a murine antibody, a chimeric antibody, a humanized antibody or a human antibody.

27. The aqueous solution of claim 1 , wherein the monoclonal antibody is present at a concentration of about 10 mg/mL to about 200 mg/mL.

28. The aqueous solution of claim 1 , wherein the monoclonal antibody is present at a concentration of about 50 mg/mL to about 200 mg/mL.

29. The aqueous solution of claim 27 , wherein the monoclonal antibody is rituximab, bevacizumab, or adalimumab.

30. The aqueous solution of claim 1 , wherein the arginine is present at a concentration of about 50 mM to about 100 mM.

31. The aqueous solution of claim 1 , wherein the methionine is present at a concentration of about 2 mM to about 30 mM.

32. The aqueous solution of claim 1 , wherein the pH of the solution is between about pH 5.0 and about pH 7.0.

33. The aqueous solution of claim 15 , wherein the buffer is selected from the group consisting of histidine, succinate, maleate, acetate, phosphate and TRIS.

34. The aqueous solution of claim 15 , wherein the buffer is present at a-concentration of about 1 mM to about 20 mM.

35. The aqueous solution of claim 15 , wherein the buffer is present at a-concentration of about 2 mM to about 5 mM.

36. The aqueous solution of claim 16 , wherein the non-ionic surfactant is an alkyl glycoside, a polysorbate surfactant, a block copolymer of polyethylene glycol and polypropylene glycol or an alkylphenyl ether of polyethylene glycol.

37. The aqueous solution of claim 16 , wherein the non-ionic surfactant is dodecyl maltoside, polysorbate 80 polysorbate 20, an alkyl ether of polyethylene glycol, poloxamer 188, poloxamer 407, poloxamer 171, poloxamer 185, or 4-(1,1,3,3-tetramethylbutyl) phenyl-polyethylene glycol.

38. The aqueous solution of claim 16 , wherein the non-ionic surfactant is dodecyl maltoside, polysorbate 80 polysorbate 20 or poloxamer 188.

39. The aqueous solution of claim 16 , wherein the non-ionic surfactant is present at a concentration of about 10 μg/mL to about 2000 μg/mL.

40. The aqueous solution of claim 17 , wherein the uncharged tonicity modifier is sucrose, trehalose, mannitol, sorbitol, PEG300 or PEG400.

41. The aqueous solution of claim 17 , wherein the uncharged tonicity modifier is present at a concentration of about 100 mM to about 500 mM, or about 300 mM.

42. The aqueous solution of claim 18 , wherein the charged tonicity modifier is sodium chloride, sodium sulphate, sodium acetate, sodium lactate, glycine or histidine.

43. The aqueous solution of claim 18 , wherein the charged tonicity modifier is present at a concentration of about 25 mM to about 500 mM.

44. The aqueous solution of claim 20 , wherein the preservative is phenol, m-cresol, chlorocresol, benzyl alcohol, propylparaben, methylparaben, benzalkonium chloride or benzethonium chloride.

45. The aqueous solution of claim 20 , wherein the preservative is present at a concentration of about 0.01 mM to about 100 mM.

46. The aqueous solution of claim 1 , wherein the arginine is present at a concentration of about 20 mM to about 100 mM.

47. The aqueous solution of claim 1 , wherein the ratio of arginine to methionine (mM/mM) is 2:1-10:1.